These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

541 related items for PubMed ID: 7522962

  • 1. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis.
    Press MF, Pike MC, Hung G, Zhou JY, Ma Y, George J, Dietz-Band J, James W, Slamon DJ, Batsakis JG.
    Cancer Res; 1994 Nov 01; 54(21):5675-82. PubMed ID: 7522962
    [Abstract] [Full Text] [Related]

  • 2. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
    Xu R, Perle MA, Inghirami G, Chan W, Delgado Y, Feiner H.
    Mod Pathol; 2002 Feb 01; 15(2):116-24. PubMed ID: 11850540
    [Abstract] [Full Text] [Related]

  • 3. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
    Latta EK, Tjan S, Parkes RK, O'Malley FP.
    Mod Pathol; 2002 Dec 01; 15(12):1318-25. PubMed ID: 12481013
    [Abstract] [Full Text] [Related]

  • 4. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma.
    Khan AJ, King BL, Smith BD, Smith GL, DiGiovanna MP, Carter D, Haffty BG.
    Clin Cancer Res; 2002 Feb 01; 8(2):540-8. PubMed ID: 11839675
    [Abstract] [Full Text] [Related]

  • 5. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
    Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, Pecorelli S.
    Cancer; 2005 Oct 01; 104(7):1391-7. PubMed ID: 16116605
    [Abstract] [Full Text] [Related]

  • 6. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival.
    Saffari B, Jones LA, el-Naggar A, Felix JC, George J, Press MF.
    Cancer Res; 1995 Dec 01; 55(23):5693-8. PubMed ID: 7585656
    [Abstract] [Full Text] [Related]

  • 7. Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland.
    Cornolti G, Ungari M, Morassi ML, Facchetti F, Rossi E, Lombardi D, Nicolai P.
    Arch Otolaryngol Head Neck Surg; 2007 Oct 01; 133(10):1031-6. PubMed ID: 17938328
    [Abstract] [Full Text] [Related]

  • 8. Prognostic significance of p27 and Ki-67 expression in mucoepidermoid carcinoma of the intraoral minor salivary gland.
    Okabe M, Inagaki H, Murase T, Inoue M, Nagai N, Eimoto T.
    Mod Pathol; 2001 Oct 01; 14(10):1008-14. PubMed ID: 11598171
    [Abstract] [Full Text] [Related]

  • 9. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing.
    Schmidt M, Lewark B, Kohlschmidt N, Glawatz C, Steiner E, Tanner B, Pilch H, Weikel W, Kölbl H, Lehr HA.
    Breast Cancer Res; 2005 Oct 01; 7(2):R256-66. PubMed ID: 15743506
    [Abstract] [Full Text] [Related]

  • 10. Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma.
    Riben MW, Malfetano JH, Nazeer T, Muraca PJ, Ambros RA, Ross JS.
    Mod Pathol; 1997 Aug 01; 10(8):823-31. PubMed ID: 9267826
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. AQUA and FISH analysis of HER-2/neu expression and amplification in a small cell lung carcinoma tissue microarray.
    Giltnane JM, Murren JR, Rimm DL, King BL.
    Histopathology; 2006 Aug 01; 49(2):161-9. PubMed ID: 16879393
    [Abstract] [Full Text] [Related]

  • 15. Non-invasive (intracapsular) carcinoma ex pleomorphic adenoma: recognition of focal carcinoma by HER-2/neu and MIB1 immunohistochemistry.
    Di Palma S, Skálová A, Vanìèek T, Simpson RH, Stárek I, Leivo I.
    Histopathology; 2005 Feb 01; 46(2):144-52. PubMed ID: 15693886
    [Abstract] [Full Text] [Related]

  • 16. Her-2/neu in barrett esophagus: a comparative study between histology, immunohistochemistry, and fluorescence in situ hybridization.
    Rossi E, Villanacci V, Bassotti G, Casa DD, Missale G, Minelli L, Cestari R.
    Diagn Mol Pathol; 2006 Sep 01; 15(3):125-30. PubMed ID: 16932066
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
    Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E.
    Cancer; 2003 Mar 15; 97(6):1573-81. PubMed ID: 12627523
    [Abstract] [Full Text] [Related]

  • 19. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization.
    Persons DL, Borelli KA, Hsu PH.
    Mod Pathol; 1997 Jul 15; 10(7):720-7. PubMed ID: 9237184
    [Abstract] [Full Text] [Related]

  • 20. Loss of Maspin expression is a negative prognostic factor in common salivary gland tumors.
    Schwarz S, Ettl T, Kleinsasser N, Hartmann A, Reichert TE, Driemel O.
    Oral Oncol; 2008 Jun 15; 44(6):563-70. PubMed ID: 17936671
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.